10/760,493

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 08  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  3  JAN 16  CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS  4  JAN 16  IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS  6  JAN 22  CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22  CA/CAplus enhanced with patent applications from India
 NEWS  8  JAN 29  PHAR reloaded with new search and display fields
 NEWS  9  JAN 29  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
 NEWS 10  FEB 15  PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15  RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23  KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13  FEB 26  MEDLINE reloaded with enhancements
 NEWS 14  FEB 26  EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26  TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26  IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26  CAS Registry Number crossover limit increased from 10,000
                  to 300,000 in multiple databases
 NEWS 18  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19  MAR 16  CASREACT coverage extended
 NEWS 20  MAR 20  MARPAT now updated daily
 NEWS 21  MAR 22  LWPI reloaded
 NEWS 22  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 27  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01  New CAS web site launched
 NEWS 29  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 30  MAY 11  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:56:05 ON 14 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

McIntosh

10/760,493

FILE 'REGISTRY' ENTERED AT 14:56:26 ON 14 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6
DICTIONARY FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10760493.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:57:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22 TO 418
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:57:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 229 TO ITERATE

100.0% PROCESSED 229 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

L3 23 SEA SSS FUL L1

=> file caplus

McIntosh

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 14:57:22 ON 14 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 13 May 2007 (20070513/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d bib abs hitstr 1-3 14

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:366398 CAPLUS
DN 145:283680
TI Improving drug discovery from microorganisms
AU Farnet, Chris M.; Zazopoulos, Emmanuel
CS Ecopia BioSciences Inc., Montreal, QC, Can.
SO Natural Products (2005), 95-106. Editor(s): Zhang, Lixin; Demain, Arnold L. Publisher: Humana Press Inc., Totowa, N. J.
CODEN: 69HZZ2; ISBN: 1-58829-383-1
DT Conference; General Review
LA English
AB A review. Microorganisms remain unrivalled in their ability to produce bioactive small mols. for drug development. However, the core technologies used to discover microbial natural products have not evolved significantly over the past several decades, resulting in a shortage of new drug leads. Advances in DNA-sequencing and bioinformatics technologies now make it possible to rapidly identify the clusters of genes that encode bioactive compds. and to make computer predictions of chemical structure based on gene sequence information. These structure predictions can be used to identify new chemical entities and provide important physicochem. "handles" that guide compound purification and structure confirmation. Industrialization of this process provides a model for improving the efficiency of natural-product discovery. The application of advanced genomics and bioinformatics technologies is now poised to revolutionize natural-product discovery and lead a renaissance of interest in microorganisms as a source of bioactive compds. for drug development.
IT 735316-93-5, ECO 02301
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ECO 02301; application of advanced genomics and bioinformatics technol. lead to development of antifungal ECO-02301 from S. aizunensis at Ecopia and evidenced microorganism as source for natural bioactive compound for drug development)
RN 735316-93-5 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

McIntosh

PAGE 1-A



PAGE 1-B



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:226855 CAPLUS
DN 142:403524
TI Microbial Genomics as a Guide to Drug Discovery and Structural Elucidation: ECO-02301, a Novel Antifungal Agent, as an Example
AU McAlpine, James B.; Bachmann, Brian O.; Piraee, Mahmood; Tremblay, Steve; Alarco, Anne-Marie; Zazopoulos, Emmanuel; Farnet, Chris M.
CS Ecopia BioSciences, Inc., Montreal, QC, H4S 2A1, Can.
SO Journal of Natural Products (2005), 68(4), 493-496
CODEN: JNPRDF; ISSN: 0163-3864
PB American Chemical Society
DT Journal
LA English
AB Anal. of the genome of Streptomyces aizunensis NRRL B-11277 indicated its potential to produce a compound of novel and highly predictable structure. The structure was predicted with sufficient accuracy to allow straightforward detection of the specific metabolite in HPLC profiles of fermentation exts. and hence to guide the isolation. The spectroscopic work was reduced to a confirmation of structure rather than a first principle determination The compound, ECO-02301, demonstrated potent antifungal activity. This work exemplifies not only the discovery of novel antibiotics from well-characterized organisms but also the utility of genomics as a further tool, complementary to spectroscopy, to enable rapid determination of complex structures.
IT 735316-93-5P, ECO 02301
RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(microbial genomics as a guide to drug discovery and structural elucidation of novel antifungal ECO-02301)
RN 735316-93-5 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:633940 CAPLUS
DN 141:167732
TI Polyene polyketides, processes for their production using polyketide synthetase genes and enzymes from Streptomyces aizunensis, and their use as fungicidal and antitumor pharmaceutical
IN Bachmann, Brian O.; Mcalpine, James B.; Zazopoulos, Emmanuel; Farnet, Chris M.
PA Ecopia Biosciences Inc., Can.
SO PCT Int. Appl., 554 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065401	A1	20040805	WO 2004-CA68	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	CA 2453071	A1	20040403	CA 2004-2453071	20040121
	CA 2453080	A1	20040403	CA 2004-2453080	20040121
	CA 2453080	C	20060221		
	US 2005187167	A1	20050825	US 2004-760493	20040121
	EP 1585752	A1	20051019	EP 2004-703730	20040121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-441123P	P	20030121		
	US 2003-469810P	P	20030513		
	US 2003-491516P	P	20030801		
	US 2003-494568P	P	20030813		
	WO 2004-CA68	W	20040121		

OS MARPAT 141:167732
GI



I

AB This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivs., and to methods for obtaining the compds. One method of obtaining these compds. is by cultivation of novel strains of Streptomyces aizunensis shown to produce polyketide I; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compds., to the use of these compds. and their pharmaceutically acceptable salts and derivs. as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. I has in vivo Candida albicans antifungal activity similar to a dose of 0.25 mg/kg of fungizone and increases 4-fold the median survival time of infected mice. I is also effective against all the human tumor cell lines that have been assayed in the NCI screening panel, suggesting a broad anticancer activity against several types of human cancer; the GI50 calculated for all cell lines was lower than 10 + 10-6M, and in some cases reached the nanomolar or picomolar level. The invention also relates to pharmaceutical compns. comprising these novel polyketides or a pharmaceutically acceptable salts or derivs. thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides. The biosynthetic locus for production of I in S. aizunensis strain NRRL B-11277 spans .apprx.176,000 bp of DNA and encodes 38 proteins.

IT 735316-93-5P
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyene polyketides, processes for their production using polyketide synthetase genes and enzymes from Streptomyces aizunensis, and their use as fungicidal and antitumor pharmaceutical)

RN 735316-93-5 CAPLUS

CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.



PAGE 1-B



IT 735316-95-7P 735316-97-9P 735316-98-0P
735316-99-1P 735317-01-8P 735317-02-9P
735317-05-2P 735317-06-3P 735317-07-4P
735317-08-5P 735317-09-6P 735317-10-9P
735317-11-0P 735317-12-1P 735317-13-2P
735317-14-3P 735317-15-4P 735317-16-5P
735317-17-6P 735317-18-7P 735317-19-8P
735317-20-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyene polyketides, processes for their production using polyketide synthetase genes and enzymes from Streptomyces aizunensis, and their use as fungicidal and antitumor pharmaceutical)

RN 735316-95-7 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,31,33,35,37,41,43,45,47,51,53-dodecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 735316-97-9 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-[(phenylmethyl)imino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 735316-98-0 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-[(phenylmethyl)imino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 735316-99-1 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenoic acid, 56-amino-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-

15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-01-8 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-amino-15,17,29,33,35,37,41,43,45,47,51,53-dodecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-02-9 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenoic acid, 56-amino-15,17,29,33,35,37,41,43,45,47,51,53-dodecahydroxy-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-05-2 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-α-L-mannopyranosyl)oxy]-56-(ethylideneamino)-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 735317-06-3 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-56-[(phenylmethylene)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 735317-07-4 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[(aminoiminomethyl)amino]-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-08-5 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-56-[(1-methylethyl)amino]-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 735317-09-6 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide,

29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,5
3-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-
56-[[(4-nitrophenyl)methyl]amino]-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 735317-10-9 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide,
56-(cyclohexylamino)-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-
15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-
cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-11-0 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-(acetylamino)-29-[(6-deoxy-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 735317-12-1 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-56-[(2-methyl-1-oxopropyl)amino]-31-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-13-2 CAPLUS
CN Benzamide, N-[28-[(6-deoxy-L-mannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 735317-14-3 CAPLUS
CN Benzamide, N-[28-[(6-deoxy-L-mannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 735317-15-4 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[[(2S)-2-amino-1-oxopropyl]amino]-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-16-5 CAPLUS
CN Benzeneacetamide, α-amino-N-[28-[(6-deoxy-α-L-mannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 735317-17-6 CAPLUS
CN Benzenepropanamide, α-amino-N-[28-[(6-deoxy-α-L-mannopyranosyl)oxy]-4,6,10,12,14,16,20,22,24,40,42-undecahydroxy-56-[(2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-27,41,43-trimethyl-31,56-dioxo-8,18,30,32,34,36,38,44,48,50,52,54-hexapentacontadodecaenyl]-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 735317-18-7 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-19-8 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo-56-[[(2S)-2-pyrrolidinylcarbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 735317-20-1 CAPLUS
CN 2,4,6,8,12,18,20,22,24,26,38,48-Hexapentacontadodecaenamide, 56-[[(2S)-2-amino-3-hydroxy-1-oxopropyl]amino]-29-[(6-deoxy-α-L-mannopyranosyl)oxy]-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-14,16,30-trimethyl-31-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B





RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:56:05 ON 14 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:56:26 ON 14 MAY 2007
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 23 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:57:22 ON 14 MAY 2007
L4 3 S L3